XML 62 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
 
Pay Versus Performance Disclosure
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and
Non-PEO
NEOs and Company performance for the fiscal years listed below. The HR and Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
 
Year
  
Summary
Compensation
Table Total for
PEO 1
($)
(1)
    
Summary
Compensation
Table Total for
PEO 2
($)
(1)
    
Compensation
Actually Paid
to PEO 1
($)
(1)(2)(3)
    
Compensation
Actually Paid
to PEO 2
($)
(1)(2)(3)
    
Average
Summary
Compensation
Table Total
for
Non-PEO

NEOs
($)
(1)
    
Average
Compensation
Actually Paid
to
Non-PEO

NEOs
($)
(1)(2)(3)
    
Value of Initial
Fixed $100
Investment based
on:
(4)
    
Net
Income
($
Millions)
    
Non-GAAP
Operating
Income
($ Millions)
(5)
  
 
TSR
($)
    
Peer
Group
TSR
($)
  
 (a)
  
(b)
    
(b)
    
(c)
    
(c)
    
(d)
    
(e)
    
(f)
    
(g)
    
(h)
    
(i)
  
2023
       25,706,880         26,191,537       4,522,802       4,825,132       106.53       124.97       (615 )      4,361  
2022
     15,529,138         17,214,057         3,977,166       4,426,020       93.06       123.43       (2,499 )
6
 		     4,139  
2021
     14,681,772         7,570,056         3,740,840       3,075,466       81.73       129.31       456       4,401  
2020
     15,724,518    
 
 
 
     10,866,321    
 
 
 
     3,997,258       3,783,167       98.47       114.32       (4,099 )      4,388  
(1)
Kåre Schultz (PEO 1) was our PEO for the years 2020 through 2022.
Richard Francis
(PEO 2) was the CEO in 2023. The individuals comprising the
Non-PEO
NEOs for each year presented are listed below.
 
 
2020
 
   
 
2021
 
   
 
2022
 
   
 
2023
 
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
 
Dr. Hafrun Fridriksdottir
   
 
Dr. Sven Dethlefs
   
 
Dr. Sven Dethlefs
   
 
Richard Daniell
 
Brendan O’Grady
   
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
   
 
Mark Sabag
(2)
The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation
S-K
and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
(3)
Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the
Non-PEO
NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic
718
. Amounts in the Exclusion of Stock Awards column are the totals from the Stock Awards columns set forth in the Summary Compensation Table.
 
Year
   
Summary Compensation
Table Total for PEO 2
($)
     
Exclusion of Stock
Awards and Option
Awards for PEO 2
($)
    
Inclusion of Equity
Values for PEO 2
($)
     
Compensation Actually
Paid to PEO 2
($)
  
2023
      25,706,880        (18,999,993 )      19,484,650        26,191,537  
 
Year
   
Average Summary
Compensation Table
Total for Non-PEO NEOs

($)
     
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO
NEOs
($)
    
Average Inclusion of
Equity Values for
Non-PEO
NEOs
($)
     
Average Compensation
Actually Paid to
Non-PEO
NEOs
($)
  
2023
      4,522,802        (2,624,988 )      2,927,317        4,825,132  
 
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
 
Year
  
Year-End
Fair
Value of
Equity Awards
Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
PEO 2
($)
    
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity Awards
for
PEO 2
($)
    
Vesting-Date

Fair Value of
Equity Awards
Granted
During Year
that Vested
During Year
for
PEO 2
($)
    
Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date
of Unvested
Equity Awards
that Vested
During Year
for
PEO 2
($)
    
Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited
During Year
for
PEO 2
($)
    
Value of
Dividends or
Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
PEO 2
($)
    
Total -
Inclusion of
Equity
Values for
PEO 2
($)
  
2023
     19,484,650       0       0       0       0       0       19,484,650  
 
Year
  
Average Year-

End Fair Value
of Equity
Awards
Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Non-PEO

NEOs
($)
    
Average
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity
Awards for
Non-PEO

NEOs
($)
    
Average
Vesting-Date
Fair Value of
Equity Awards
Granted
During Year
that Vested
During Year
for Non-PEO

NEOs
($)
    
Average
Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date
of Unvested
Equity Awards
that Vested
During Year
for
Non-PEO

NEOs
($)
    
Average Fair
Value at Last
Day of Prior
Year of Equity
Awards
Forfeited
During Year
for
Non-PEO

NEOs
($)
    
Average Value
of Dividends
or Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
Non-PEO

NEOs
($)
    
Total - Average

Inclusion of
Equity Values
for Non-PEO

NEOs
($)
  
2023
     2,729,569       92,894       0       104,854       0       0       2,927,317  
(4)
The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation
S-K
included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Total Return Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
(5)
We determined
Non-GAAP
Operating Income to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and
Non-PEO
NEOs in 2023. Please see “Executive Compensation—Compensation Discussion and Analysis—IV. Components of Our Compensation Program—Long-Term Incentive Equity-Based Compensation” above for a description of how
Non-GAAP
Operating Income is determined. This performance measure may not have been the most important financial performance measure for years 2022, 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
(6)
The amount set forth for Net Income in 2022 has been updated in connection with a revision made in 2023. Please see note 1b to the consolidated financial statements included in the Annual Report on Form
10-K
for the year ended December 31, 2023.
     
Company Selected Measure Name Non-GAAP Operating Income      
Named Executive Officers, Footnote
 
2020
 
   
 
2021
 
   
 
2022
 
   
 
2023
 
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
 
Dr. Hafrun Fridriksdottir
   
 
Dr. Sven Dethlefs
   
 
Dr. Sven Dethlefs
   
 
Richard Daniell
 
Brendan O’Grady
   
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
   
 
Mark Sabag
      
Peer Group Issuers, Footnote The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation
S-K
included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Total Return Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. 		     
PEO Total Compensation Amount $ 25,706,880 $ 15,529,138 $ 14,681,772 $ 15,724,518
PEO Actually Paid Compensation Amount $ 26,191,537 17,214,057 7,570,056 10,866,321
Adjustment To PEO Compensation, Footnote
Year
   
Summary Compensation
Table Total for PEO 2
($)
     
Exclusion of Stock
Awards and Option
Awards for PEO 2
($)
    
Inclusion of Equity
Values for PEO 2
($)
     
Compensation Actually
Paid to PEO 2
($)
  
2023
      25,706,880        (18,999,993 )      19,484,650        26,191,537  
      
Non-PEO NEO Average Total Compensation Amount $ 4,522,802 3,977,166 3,740,840 3,997,258
Non-PEO NEO Average Compensation Actually Paid Amount $ 4,825,132 4,426,020 3,075,466 3,783,167
Adjustment to Non-PEO NEO Compensation Footnote
Year
   
Average Summary
Compensation Table
Total for Non-PEO NEOs

($)
     
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO
NEOs
($)
    
Average Inclusion of
Equity Values for
Non-PEO
NEOs
($)
     
Average Compensation
Actually Paid to
Non-PEO
NEOs
($)
  
2023
      4,522,802        (2,624,988 )      2,927,317        4,825,132  
      
Compensation Actually Paid vs. Total Shareholder Return
Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and Total Shareholder Return (“TSR”)
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and the cumulative TSR over the four most recently completed fiscal years for the Company and the Dow Jones U.S. Select Pharmaceuticals Total Return Index.
 
LOGO
     
Compensation Actually Paid vs. Net Income
Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and our Net Income during the four most recently completed fiscal years.
 
LOGO
 
      
Compensation Actually Paid vs. Company Selected Measure
Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and
Non-GAAP
Operating Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and our
Non-GAAP
Operating Income during the four most recently completed fiscal years.
 
LOGO
     
Total Shareholder Return Vs Peer Group
Relationship Between Company TSR and Peer Group TSR
The following chart compares our cumulative TSR over the four most recently completed fiscal years to that of the Dow Jones U.S. Select Pharmaceuticals Total Return Index over the same period.
 
LOGO
     
Tabular List, Table
Tabular List of Most Important Financial and
Non-Financial
Performance Measures
The following table presents the financial and
non-financial
performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and other NEOs for 2023 to Company performance. The measures in this table are not ranked.
 
Non-GAAP
Operating Income
Net Revenue from Innovative Products
Net Revenue from All Other Products
Relative TSR
Non-GAAP
Earnings Per Share
Free Cash Flow
      
Total Shareholder Return Amount $ 106.53 93.06 81.73 98.47
Peer Group Total Shareholder Return Amount 124.97 123.43 129.31 114.32
Net Income (Loss) $ (615,000,000) $ (2,499,000,000) $ 456,000,000 $ (4,099,000,000)
Company Selected Measure Amount 4,361,000,000 4,139,000,000 4,401,000,000 4,388,000,000
PEO Name Richard Francis Kåre Schultz Kåre Schultz Kåre Schultz
Measure:: 1        
Pay vs Performance Disclosure        
Name Non-GAAP Operating Income      
Non-GAAP Measure Description We determined
Non-GAAP
Operating Income to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and
Non-PEO
NEOs in 2023. Please see “Executive Compensation—Compensation Discussion and Analysis—IV. Components of Our Compensation Program—Long-Term Incentive Equity-Based Compensation” above for a description of how
Non-GAAP
Operating Income is determined. This performance measure may not have been the most important financial performance measure for years 2022, 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years. 		     
Measure:: 2        
Pay vs Performance Disclosure        
Name Net Revenue from Innovative Products      
Measure:: 3        
Pay vs Performance Disclosure        
Name Net Revenue from All Other Products      
Measure:: 4        
Pay vs Performance Disclosure        
Name Relative TSR      
Measure:: 5        
Pay vs Performance Disclosure        
Name Non-GAAP Earnings Per Share      
Measure:: 6        
Pay vs Performance Disclosure        
Name Free Cash Flow      
PEO | Exclusion of Stock Awards and Option Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (18,999,993)      
PEO | Inclusion of Equity Values [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 19,484,650      
PEO | YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 19,484,650      
PEO | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Exclusion of Stock Awards and Option Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (2,624,988)      
Non-PEO NEO | Inclusion of Equity Values [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,927,317      
Non-PEO NEO | YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,729,569      
Non-PEO NEO | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 92,894      
Non-PEO NEO | VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 104,854      
Non-PEO NEO | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0